A recent posting by the FDA informs that Sandoz, a Division of the Novartis group, has issued a voluntary recall of a batch of Estarylla tablets. Estarylla (norgestimate and ethinyl estradiol) is a combination oral contraceptive. The recall was prompted by a packaging flaw. In particular, the affected lot had placebo tablets mixed with regular tablets containing the active ingredients. According to Sandoz, "the probability of adverse events is minimal, as the packaging flaw is easily visible and the risk of pregnancy occurring after non-administration of one blue tablet is low."
Source: FDA, http://www.fda.gov/Safety/Recalls/ucm359613.htm